Be a PRO & get up to 50% off on select brands. Explore Now
you are here: HomeNewsTrendsHealth

Remdesivir marketing companies to supply 53 lakh vials for April 21-May 16 period to states/ UTs: Govt

"The companies have been instructed to ensure timely supplies to all states/ UTs strictly as per the supply plan," the Ministry of Chemicals and Fertilizers said in a statement.

May 08, 2021 / 03:51 PM IST
(Image: Reuters)

(Image: Reuters)

Marketing companies of remdesivir, used in the treatment of COVID-19 patients, will supply 53 lakh vials of the antiviral drug to the states/UTs for the period between April 21 and May 16, the Ministry of Chemicals and Fertilizers said in a statement on Saturday.

"The companies have been instructed to ensure timely supplies to all states/ UTs strictly as per the supply plan," it added.

Also Read: Centre revises policy, COVID-19 positive test report no longer mandatory for admission to hospital

In continuation to the allocation of remdesivir to states/UTs done on Friday, the company-wise supply plan of the drug  for the period April 21 to May 16 has been issued to states/UTs. The plan has been prepared in consultation with the marketing companies, the ministry said.

Follow our LIVE blog for latest updates of the novel coronavirus pandemic


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

To ensure smooth supply of remdesivir, the allocation of the drug to the states and Union Territories has been made up to May 16, Union Chemicals and Fertilisers Minister Sadananda Gowda said on Friday.

Also Read: COVID-19: Turmeric milk, dark chocolate among Centre's list of foods that boost immunity

As per the supply plan, while Zydus Cadila is to supply a total of 982,100 vials of remdesivir for the April 21-May 16 period to the states/ UTs, Hetero will supply 1,717,050 vials for the duration, the Ministry of Chemicals and Fertilizers said.

For the period, Mylan will supply 7,28,000 vials and Cipla is to supply 7,32,300 vials of the drug to the states/UTs, it added.

While Jubilant will supply 4,45,700 vials of remdesivir for the period, Syngene/Sun is to supply 3,73,000 vials and Dr Reddy's will supply 3,21,850 vials of the critical drug between April 21 to May 16, the statement said.

Demand for remdesivir has gone up manifold in the country amid a massive spike in COVID-19 infections.

The government has already waived customs duty on remdesivir, its raw materials and other components used to make the antiviral drug in order to help augment domestic availability and reduce the cost of the injection.

On April 11, in view of increased demand for remdesivir, the Centre banned the export of the injection and its active pharmaceutical ingredients (APIs) till the situation improves.

Follow our full coverage of the coronavirus pandemic here.

stay updated

Get Daily News on your Browser